highly significantP = 0.001
The first clinical report evaluating HCQ for the treatment of COVID-19 was an observational study of 20 patients treated in France with HCQ and found at day 6 post-inclusion, 70% of HCQ-treated patients were virologically cured compared with 12.5% in a control group (reported as highly significant, P = 0.001).